Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

BACKGROUND: CPX-351, a liposomal formulation of cytarabine and daunorubicin co-encapsulated at an optimized synergistic 5:1 molar ratio, has demonstrated improved clinical outcomes over conventional cytarabine/daunorubicin treatment in a randomized phase 2 trial in patients with AML as well as super...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pediatr Blood Cancer
Egile Nagusiak: Carol, Hernan, Fan, Mannie M. Y., Harasym, Troy O., Boehm, Ingrid, Mayer, Lawrence D., Houghton, Peter, Smith, Malcolm, Lock, Richard B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237711/
https://ncbi.nlm.nih.gov/pubmed/25203866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25133
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak